eli lilly and company zepbound

News

Eli Lilly, Zepbound

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

· 2d

· 2d · on MSN

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

· 13d · on MSN

Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health

Hosted on MSN2d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

The discontinuation rate due to side effects was 6.1% for Zepbound and 8% for Wegovy. On Stocktwits, sentiment toward Eli ...

13d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Yahoo Finance3d

Eli Lilly and Company (LLY)

Zepbound helped nearly 25% more participants lose more than 15% of their weight compared to Wegovy, Lilly said on Sunday. Eli Lilly and Company (NYSE: LLY) today announced detailed results ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results